RxDoctor Payments Data

Htoo Kyaw, MD

Cardiovascular Disease · Bakersfield, CANPI 1669873949

Payments from drug & device makers

$37,590in general payments, 2019–2025

Across 438 payments — averaging $85.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$27K
  • Cardiovascular Systems Inc.$1K
  • Shockwave Medical, Inc$1K
  • Boston Scientific$1K
  • Amgen$971
  • AstraZeneca$712
  • plus $6K from 28 others

What the payments were for

  • Grants$25,17867%
  • Food & beverage$11,92532%
  • Education$4861%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,590 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$301,409
Medicare patients
1,687
Services billed
2,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten20$164,761
OpsumitMacitentan13$154,243
EliquisApixaban28$35,031
ClopidogrelClopidogrel Bisulfate106$1,432
Metoprolol Succinate52$545
Atorvastatin Calcium56$537
Carvedilol34$326
Isosorbide Mononitrate ErIsosorbide Mononitrate42$311
Furosemide19$237
Losartan Potassium18$192
Lisinopril14$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$468$164,76120 claims
Actelion Pharmaceuticals US, Inc.Opsumit$202$154,24313 claims
PfizerEliquis$613$35,03128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →